Terminated/Withdrawn

Lymphoma, Mantle-Cell

Bayer Identifier:

17120

ClinicalTrials.gov Identifier:

NCT02455297

EudraCT Number:

Not Available

EU CT Number:

Not Available

Phase IIa study of copanlisib in relapsed or refractory mantle cell lymphoma (MCL)

Trial purpose

The primary objective of this study is to assess objective response rate (ORR) in patients with relapsed or refractory MCL who failed ibrutinib treatment or were unable to tolerate ibrutinib.

Key Participants Requirements

Sex

Both

Age

18 - N/A

Inclusion Criteria
- Histologically confirmed MCL
- Patients who have previously received treatment with ibrutinib (modified by amendment 1), including:
-- Completion of at least 1 cycle of treatment with ibrutinib and confirmed evidence of disease progression or refractoriness to treatment or
-- Discontinuation of ibrutinib treatment at an earlier time due to toxicity
- Measurable disease according to the Lugano Classification
- At least 28 days or 5 half-lives, whichever is shorter, from the completion of anti-cancer treatment (including, but not limited to, immunotherapy, chemotherapy, targeted therapy and biologic therapy) to the start of study treatment, excluding ibrutinib where the window may be less and at minimum 3 days (modified by amendment 1)
- Availability of fresh tumor tissue at screening
- Male or female patients ≥ 18 years old
- ECOG (Eastern Cooperative Oncology Group) performance status of ≤ 2
- Left ventricular ejection fraction (LVEF) by echocardiogram or multiple gated acquisition (MUGA) scan ≥ the lower limit of normal (LLN) for the Institution
- Adequate bone marrow, liver and renal function
Exclusion Criteria
- Any of the following as the only site(s) of disease: palpable lymph nodes not visible on imaging studies, skin lesions, or bone marrow involvement only
- Current central nervous system (CNS) involvement by lymphoma
- New York Heart Association (NYHA) class III or IV heart disease
- Unstable angina (angina symptoms at rest), new-onset angina (begun within the last 3 months). Myocardial infarction less than 6 months before start of study treatment
- Uncontrolled arterial hypertension despite optimal medical management (per investigator’s assessment) (modified by amendment 1)
- Type I or II diabetes mellitus with HbA1c > 8.5% at screening (modified by amendment 1)
- Arterial or venous thrombotic or embolic events such as cerebrovascular accident (including transient ischemic attacks), deep vein thrombosis or pulmonary embolism within 3 months before start of study treatment. However, if a patient has recovered to ECOG performance status of ≤ 2 he/she may be enrolled provided that other eligibility criteria are met
- Ongoing or active infection of Common Terminology Criteria for Adverse Events (CTCAE) Grade ≥ 3
- Known history of human immunodeficiency virus (HIV) infection
- Acute or chronic hepatitis B (HBV) or hepatitis C (HCV) infection requiring concomitant treatment prohibited by this protocol (i.e.immunosuppressive therapy)
- History or concurrent condition of interstitial lung disease of any severity and/or severely impaired lung function (as judged by the investigator)
- Prior treatment with PI3K inhibitor(s)
- Cytomegalovirus (CMV) PCR positive at baseline

Trial summary

Enrollment Goal

Trial Dates

August 2015 - August 2016

Phase

Phase 2

Could I Receive a placebo

Products

Aliqopa (Copanlisib, BAY80-6946)

Accepts Healthy Volunteer

Where to participate

Status	Institution	Location
Terminated		New York, 10021, United States
Terminated		New York, 10029, United States
Terminated		Hackensack, 07601, United States
Terminated		Baltimore, 21287, United States
Terminated		Burlington, 05401, United States

Primary Outcome

Objective response rate (ORR)
ORR is defined as the proportion of patients who have a best overall response of complete response (CR) or partial response (PR) during study conduct according to the criteria defined by the Lugano response criteria in NHL 2014.
Time Frame:
24 weeks
Safety Issue:
No

Secondary Outcome

Complete response rate (CRR)
Defined as the proportion of patients who have a best overall response of CR during study conduct according to the criteria defined by the Lugano response criteria in NHL 2014
Time Frame:
24 weeks
Safety Issue:
No
Disease control rate (DCR)
Defined as the proportion of patients who have a best response of CR, PR, or stable disease (SD)
Time Frame:
24 weeks
Safety Issue:
No
Progression-free survival (PFS)
Defined as the time (in days) from the date of first administration of study treatment to radiological disease progression or death from any cause (if death occurs before radiological progression is documented). PFS for patients without radiological progression or death at the time of analysis will be censored at the last date of evaluable tumor assessment. PFS for alive patients who have no tumor assessments after baseline will be censored at day 1.
Time Frame:
24 weeks
Safety Issue:
No
Duration of response (DOR)
Defined as the time (in days) from the date of first observed tumor response of CR or PR, whichever was noted earlier, to radiological disease progression or death from any cause (if death occurs before radiological progression is documented)
Time Frame:
24 weeks
Safety Issue:
No
Overall survival (OS)
Defined as the time (in days) from the date of first administration of study treatment to death from any cause. The OS time for patients alive at the time of analysis will be censored at their last known alive date.
Time Frame:
24 weeks
Safety Issue:
No
Number of participants with treatment emergent adverse events (TEAEs) as a measure of safety and tolerability
Time Frame:
Approximately 7 months
Safety Issue:
Yes

Trial design

A single-arm, open-label Phase IIa study to evaluate the efficacy and safety of copanlisib monotherapy in patients with relapsed or refractory mantle cell lymphoma (MCL), who failed ibrutinib treatment or were unable to tolerate ibrutinib

Trial Type

Interventional

Intervention Type

Drug

Trial Purpose

Treatment

Allocation

N/A

Blinding

Open Label

Assignment

Single Group Assignment

Trial Arms

Additional Information

Click here and search for drug information provided by the FDA.Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product.Click here to find results for studies related to Bayer products.